CA3194229A1 - Hla class ii-restricted dq t cell receptors against ras with g13d mutation - Google Patents
Hla class ii-restricted dq t cell receptors against ras with g13d mutationInfo
- Publication number
- CA3194229A1 CA3194229A1 CA3194229A CA3194229A CA3194229A1 CA 3194229 A1 CA3194229 A1 CA 3194229A1 CA 3194229 A CA3194229 A CA 3194229A CA 3194229 A CA3194229 A CA 3194229A CA 3194229 A1 CA3194229 A1 CA 3194229A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- amino acid
- acid sequence
- leu
- ile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
- A61K40/4253—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063086674P | 2020-10-02 | 2020-10-02 | |
| US63/086,674 | 2020-10-02 | ||
| PCT/US2021/053060 WO2022072760A1 (en) | 2020-10-02 | 2021-10-01 | Hla class ii-restricted dq t cell receptors against ras with g13d mutation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3194229A1 true CA3194229A1 (en) | 2022-04-07 |
Family
ID=78676633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3194229A Pending CA3194229A1 (en) | 2020-10-02 | 2021-10-01 | Hla class ii-restricted dq t cell receptors against ras with g13d mutation |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12655195B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4222169A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7850143B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230084524A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116710111A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021351710A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3194229A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB2615010A (cg-RX-API-DMAC7.html) |
| TW (2) | TW202540156A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022072760A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024513651A (ja) | 2021-02-26 | 2024-03-27 | ニューヨーク ユニバーシティ | 共有結合性ペプチドコンジュゲートに結合する抗体を含む組成物及び方法 |
| WO2025056685A1 (en) * | 2023-09-15 | 2025-03-20 | Medigene Immunotherapies Gmbh | T-CELL RECEPTOR AGAINST mKRAS7-16 G12V |
| WO2026024602A2 (en) * | 2024-07-22 | 2026-01-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors against ras with g12d, g12v, g13d or q61r mutation |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8034334B2 (en) | 2002-09-06 | 2011-10-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
| US20100286143A1 (en) * | 2009-04-24 | 2010-11-11 | Dora Dias-Santagata | Methods and materials for genetic analysis of tumors |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| US20140134158A1 (en) * | 2012-05-22 | 2014-05-15 | Alberto Bardelli | Kras mutations and resistance to anti-egfr treatment |
| SG10201913978RA (en) | 2014-11-26 | 2020-03-30 | The United States Of America As Represented By The Secretary | Anti-mutated kras t cell receptors |
| JP2018518177A (ja) | 2015-06-16 | 2018-07-12 | タルゴバックス エーエスエー | Rasタンパク質の突然変異フラグメント |
| SG10201913868XA (en) | 2015-09-15 | 2020-03-30 | The United States Of America As Represented By The Secretary | T cell receptors recognizing hla-cw8 restricted mutated kras |
| US20170319638A1 (en) | 2016-05-06 | 2017-11-09 | Virttu Biologics Limited | Treatment of cancer |
| GB201608052D0 (en) * | 2016-05-09 | 2016-06-22 | Univ Oslo Hf | T-cell receptors which recognise frameshift mutants of TGF-beta RII |
| SG11201900654QA (en) | 2016-08-02 | 2019-02-27 | Us Health | Anti-kras-g12d t cell receptors |
| KR20190062505A (ko) * | 2016-10-03 | 2019-06-05 | 주노 쎄러퓨티크스 인코퍼레이티드 | Hpv-특이적 결합 분자 |
| CN108395479B (zh) | 2017-02-06 | 2021-07-16 | 高军 | 一种有关kras基因突变的t细胞受体 |
| AU2018335274B2 (en) | 2017-09-20 | 2025-02-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HLA class II–restricted T cell receptors against mutated RAS |
| WO2019069125A1 (en) * | 2017-10-06 | 2019-04-11 | Oslo Universitetssykehus Hf | CHIMERIC ANTIGEN RECEPTORS |
| MX2020005765A (es) * | 2017-12-04 | 2020-09-25 | Us Health | Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado. |
| CN112585276A (zh) | 2018-04-05 | 2021-03-30 | 朱诺治疗学股份有限公司 | 产生表达重组受体的细胞的方法和相关组合物 |
| SG11202012653XA (en) * | 2018-06-19 | 2021-01-28 | Biontech Us Inc | Neoantigens and uses thereof |
| AU2019321608B2 (en) | 2018-08-16 | 2024-07-25 | Biontech Us Inc. | T cell receptor constructs and uses thereof |
| US20220313803A1 (en) * | 2019-01-07 | 2022-10-06 | Brightpath Biotherapeutics Co., Ltd. | Novel neoantigens and cancer immunotherapy using same |
| WO2020150364A1 (en) * | 2019-01-15 | 2020-07-23 | Altor Bioscience, Llc | Human immunodeficiency virus-specific t cell receptors |
| CA3127673A1 (en) | 2019-01-25 | 2020-07-30 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting mutant ras |
| WO2020191365A1 (en) * | 2019-03-21 | 2020-09-24 | Gigamune, Inc. | Engineered cells expressing anti-viral t cell receptors and methods of use thereof |
| MX2021015946A (es) * | 2019-06-18 | 2022-04-18 | Regeneron Pharma | Receptores de linfocitos t de mage-a4 y métodos de uso de estos. |
| DE102019121007A1 (de) * | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| CA3168015A1 (en) | 2020-02-12 | 2021-08-19 | Noam LEVIN | Hla class i-restricted t cell receptors against ras with g12d mutation |
| AU2021227406A1 (en) | 2020-02-24 | 2022-09-29 | Oblique Therapeutics Ab | Kras epitopes and antibodies |
| WO2021250511A1 (ko) * | 2020-06-10 | 2021-12-16 | 주식회사 유틸렉스 | Mr1에 결합하는 t-세포 수용체 및 이의 용도 |
-
2021
- 2021-10-01 AU AU2021351710A patent/AU2021351710A1/en active Pending
- 2021-10-01 JP JP2023520143A patent/JP7850143B2/ja active Active
- 2021-10-01 TW TW114122865A patent/TW202540156A/zh unknown
- 2021-10-01 CN CN202180072524.XA patent/CN116710111A/zh active Pending
- 2021-10-01 EP EP21810460.2A patent/EP4222169A1/en active Pending
- 2021-10-01 WO PCT/US2021/053060 patent/WO2022072760A1/en not_active Ceased
- 2021-10-01 KR KR1020237014854A patent/KR20230084524A/ko active Pending
- 2021-10-01 CA CA3194229A patent/CA3194229A1/en active Pending
- 2021-10-01 GB GB2305617.9A patent/GB2615010A/en active Pending
- 2021-10-01 TW TW110136658A patent/TW202229327A/zh unknown
- 2021-10-01 US US18/027,981 patent/US12655195B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20230365649A1 (en) | 2023-11-16 |
| CN116710111A (zh) | 2023-09-05 |
| GB2615010A (en) | 2023-07-26 |
| KR20230084524A (ko) | 2023-06-13 |
| JP2023544592A (ja) | 2023-10-24 |
| TW202540156A (zh) | 2025-10-16 |
| AU2021351710A9 (en) | 2025-03-20 |
| EP4222169A1 (en) | 2023-08-09 |
| US12655195B2 (en) | 2026-06-16 |
| TW202229327A (zh) | 2022-08-01 |
| GB202305617D0 (en) | 2023-05-31 |
| JP7850143B2 (ja) | 2026-04-22 |
| WO2022072760A1 (en) | 2022-04-07 |
| AU2021351710A1 (en) | 2023-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3084246A1 (en) | Hla class i-restricted t cell receptors against mutated ras | |
| US20230080742A1 (en) | Hla class i-restricted t cell receptors against ras with g12d mutation | |
| CN108350059A (zh) | 识别hla-cw8限制性突变kras的t细胞受体 | |
| US20230082787A1 (en) | Hla class i-restricted t cell receptors against ras with g12v mutation | |
| CA3116749A1 (en) | Hla-a3-restricted t cell receptors against mutated ras | |
| US20230159614A1 (en) | Hla class ii-restricted t cell receptors against ras with g12v mutation | |
| JP7850143B2 (ja) | G13d変異を有するrasに対するhlaクラスii拘束性dq t細胞受容体 | |
| US20230272038A1 (en) | Hla class ii-restricted drb t cell receptors against ras with g12d mutation | |
| US12577286B2 (en) | T cell receptors which recognize mutated EGFR | |
| US20230321240A1 (en) | T cell receptors recognizing r273c or y220c mutations in p53 | |
| US20230257440A1 (en) | Hla class ii-restricted drb t cell receptors against ras with g12v mutation | |
| US20240190940A1 (en) | Hla class i-restricted t cell receptors against ras with q61k mutation | |
| US20230312672A1 (en) | Hla class i-restricted t cell receptors against cd20 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240927 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240927 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240927 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20250909 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250909 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250909 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250909 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250926 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250926 |